The AKR1C3 rs12529 polymorphism is known to interact with AR-CAG repeat lengths in increasing prostate cancer-specific mortality while on ADT by up to 13.7 fold36, and highly correlated with the AKR1C3 rs1937845 promoter polymorphism71. Here, AR is linked to prostate cancer.